Clinical Trial Update: Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating arsenic trioxide in combination with gemtuzumab ozogamicin for advanced myelodysplastic syndromes (and associated leukemia); t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Arsenic Trioxide (arsenic trioxide)
• Gemtuzumab ozogamicin (gemtuzumab ozogamicin)

Snippet

Sponsor: The Cleveland Clinic | Conditions: Leukemia, Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2015-07-10